Global Personalized Cell Therapy Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of Chronic Diseases
The global Personalized Cell Therapy market is estimated to be valued at USD 12,572.34 Mn in 2022 and is expected to exhibit a CAGR of 24% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights.
A) Market Overview:
Personalized Cell Therapy involves the utilization of a patient's own cells to treat various diseases. These cells are modified and reprogrammed to enhance their therapeutic properties and then reintroduced into the patient's body. The aim of personalized cell therapy is to provide targeted and individualized treatment options that have fewer side effects and better efficacy compared to conventional therapies. The development and adoption of personalized cell therapies have gained significant momentum in recent years, leading to extensive research and advancements in this field.
B) Market Dynamics:
The Personalized Cell Therapy Market is primarily driven by two key factors: the increasing prevalence of chronic diseases and the growing demand for advanced cell therapies. With the rising incidence of diseases such as cancer, cardiovascular disorders, and autoimmune diseases, there is a pressing need for more effective and targeted treatment options. Personalized cell therapies offer a promising solution, as they can be tailored to the specific needs of each patient, resulting in better treatment outcomes. Additionally, advancements in cell engineering and reprogramming techniques have paved the way for the development of more sophisticated and efficacious cell therapies.
An example of a driver is the increasing prevalence of cancer. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, accounting for an estimated 9.6 million deaths in 2018. The use of personalized cell therapies, such as CAR-T cell therapy, has shown promising results in treating certain types of cancer, especially hematological malignancies. CAR-T cell therapy involves modifying a patient's own T cells to express chimeric antigen receptors (CARs) that target specific cancer cells. This targeted approach has demonstrated remarkable success in achieving complete remission in patients with relapsed or refractory leukemia and lymphoma.
C) Segment Analysis:
The Personalized Cell Therapy Market can be segmented based on the type of therapy, application, and end-user. The dominant segment in the market is expected to be the cancer therapy segment, as personalized cell therapies have shown promising results in treating various types of cancer. The growing adoption of CAR-T cell therapy and the development of novel cell-based immunotherapies are driving the growth of this segment.
D) PEST Analysis:
- Political: Supportive government initiatives and regulatory frameworks are expected to facilitate the development and commercialization of personalized cell therapies.
- Economic: The growing demand for personalized cell therapies is expected to drive economic growth through increased investments in research and development.
- Social: There is a growing awareness and acceptance of personalized cell therapies among patients and healthcare professionals.
- Technological: Advances in cell engineering, gene editing, and reprogramming techniques are driving the development of more effective and targeted cell therapies.
E) Key Takeaways:
- The global Personalized Cell Therapy market is expected to witness high growth, exhibiting a CAGR of 24% over the forecast period, due to increasing prevalence of chronic diseases and growing demand for advanced cell therapies.
- North America is expected to dominate the market, followed by Europe, due to the presence of well-established healthcare infrastructure, favorable reimbursement policies, and significant investments in research and development.
- Key players operating in the global Personalized Cell Therapy market are Cytori Therapeutics Inc., Bellicum Pharmaceuticals, Inc., Saneron CCEL Therapeutics, Inc., MolMed S.p.A., Vericel Corporation, Novartis AG, Gilead Sciences, Inc., Celgene Corporation, Bluebird Bio, Inc., and Aurora Biopharma Inc. These players are actively involved in research and development activities to introduce innovative cell therapy products and expand their market presence.
In conclusion, the global Personalized Cell Therapy market is poised for significant growth due to the increasing prevalence of chronic diseases and the demand for more targeted and effective treatment options. The advancements in cell engineering and reprogramming techniques have paved the way for the development of personalized cell
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian